Cross-sectional associations between angiotensin-converting enzyme inhibitor use and cancer diagnosis in US adults.
Por:
Smith L, Parris C, Veronese N, Shang C, López-Sánchez GF, Jacob L, Koyanagi A, Nottegar A, Jackson SE, Raupach T, Grabovac I, Crichton S, Dempsey F and Yang L
Publicada:
1 ago 2020
Ahead of Print:
26 mar 2020
Resumen:
The objective of the present study was to investigate the association between angiotensin-converting enzyme (ACE) inhibitor use and cancer incidence (overall, and breast, prostate, and colorectal cancers specifically) in a large representative sample of US adults. Cross-sectional data on cancer diagnosis, timing of cancer diagnosis, ACE inhibitor use, and other characteristics were extracted from 49 512 adults aged = 20 years participating in the National Health and Nutrition Examination Survey (1999-2016). Multivariable-logistic and propensity score matching (PSM) regressions examined the relationship between pre-diagnosis use of ACE inhibitors and diagnosis of all cancers, and breast, prostate, and colorectal cancers specifically. Overall, we observed an increased likelihood of cancer diagnosis [odds ratio (OR) 1.269, 95% confidence interval (CI) 1.088-1.480] among those who used ACE inhibitors compared to non-ACE inhibitor use, and for prostate cancer diagnosis (OR 1.438, 95% CI 1.090-1.897), after adjusting for age, sex, body mass index, race/ethnicity, educational attainment, physical activity, alcohol drinking status, smoking status, and high blood pressure. PSM regression retrieved more conservative estimates such that the increased likelihood of cancer diagnosis was only observed when comparing ACE inhibitor users with non-drug users (OR 1.022, 95% CI 1.016-1.027). Compared with non-ACE inhibitor use, ACE inhibitor use was associated with an increased risk of prostate cancer. In conclusion, in this large representative sample of US adults, it was found that ACE inhibitor use may have a marginal influence on some cancers.
Filiaciones:
Smith L:
The Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge, UK.
Parris C:
Biomedical Research Group, Faculty of Science and Engineering, Anglia Ruskin University, Cambridge, UK
Veronese N:
Aging Branch, Neuroscience Institute, National Research Council, Padua, Italy
Shang C:
Stephenson Cancer Centre, University of Oklahoma Health Social Science Centre, Oklahoma City, USA
López-Sánchez GF:
Faculty of Sport Sciences, University of Murcia, Murcia, Spain
Jacob L:
Faculty of Medicine, University of Versailles Saint-Quentin-en-Yvelines, 78180, Montigny-le-Bretonneux, France
Koyanagi A:
Research and Development Unit, Parc Sanitari Sant Joan de Déu, CIBERSAM, Sant Boi de Llobregat, Barcelona, Spain
Nottegar A:
Department of Surgery, Section of Pathology, San Bortolo Hospital, Vicenza, Italy
Jackson SE:
Department of Behavioural Science and Health, University College London, London, UK
Raupach T:
Department of Cardiology and Pneumology, University Medical Centre GoEttingen, Goettingen, Germany
Grabovac I:
Department of Social and Preventive Medicine, Center for Public Health, Medical University of Vienna, Vienna, Austria
Crichton S:
MedAnnex Ltd, 1 Summerhall Place, Techcube 3.5, Edinburgh, EH9 1PL, UK
Dempsey F:
MedAnnex Ltd, 1 Summerhall Place, Techcube 3.5, Edinburgh, EH9 1PL, UK
Yang L:
Department of Cancer Epidemiology and Prevention Research, Alberta Health Services, Holy Cross Centre, Calgary, Canada.
Departments of Oncology and Community Health Sciences, University of Calgary, Calgary, Canada.
Green Submitted, Green Accepted
|